| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Zai Lab Limited (NASDAQ: ZLAB)
ZLAB Technical Analysis
5
| As on 31st Jul 2025 ZLAB SHARE Price closed @ 37.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 21.20 & Strong Buy for SHORT-TERM with Stoploss of 17.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ZLABSHARE Price
| Open | 37.28 | Change | Price | % |
| High | 38.34 | 1 Day | -0.77 | -2.00 |
| Low | 36.80 | 1 Week | 0.80 | 2.16 |
| Close | 37.80 | 1 Month | 0.58 | 1.56 |
| Volume | 821605 | 1 Year | 20.07 | 113.20 |
| 52 Week High 43.03 | 52 Week Low 13.72 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| HCTI | 0.03 | 0.00% |
| SNGX | 2.93 | 134.40% |
| NVDA | 177.87 | -0.78% |
| VRME | 1.39 | 101.45% |
| LMDX | 0.02 | 0.00% |
| SOFI | 22.58 | 3.25% |
| NCNA | 0.04 | -20.00% |
| OPEN | 1.84 | -11.11% |
| AKTS | 0.04 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ZLAB Daily Charts |
ZLAB Intraday Charts |
Whats New @ Bazaartrend |
ZLAB Free Analysis |
|
|
ZLAB Important Levels Intraday
| RESISTANCE | 40.77 |
| RESISTANCE | 39.82 |
| RESISTANCE | 39.23 |
| RESISTANCE | 38.64 |
| SUPPORT | 36.96 |
| SUPPORT | 36.37 |
| SUPPORT | 35.78 |
| SUPPORT | 34.83 |
ZLAB Forecast August 2025
| 4th UP Forecast | 51.42 |
| 3rd UP Forecast | 47.05 |
| 2nd UP Forecast | 44.35 |
| 1st UP Forecast | 41.65 |
| 1st DOWN Forecast | 33.95 |
| 2nd DOWN Forecast | 31.25 |
| 3rd DOWN Forecast | 28.55 |
| 4th DOWN Forecast | 24.18 |
ZLAB Weekly Forecast
| 4th UP Forecast | 45.68 |
| 3rd UP Forecast | 43.15 |
| 2nd UP Forecast | 41.59 |
| 1st UP Forecast | 40.03 |
| 1st DOWN Forecast | 35.57 |
| 2nd DOWN Forecast | 34.01 |
| 3rd DOWN Forecast | 32.45 |
| 4th DOWN Forecast | 29.92 |
ZLAB Forecast2025
| 4th UP Forecast | 97.27 |
| 3rd UP Forecast | 78.2 |
| 2nd UP Forecast | 66.41 |
| 1st UP Forecast | 54.62 |
| 1st DOWN Forecast | 20.98 |
| 2nd DOWN Forecast | 9.19 |
| 3rd DOWN Forecast | -2.6 |
| 4th DOWN Forecast | -21.67 |
Zai Lab Limited ( NASDAQ USA Symbol : ZLAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ZLAB Business Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, and infectious diseases primarily in Greater China. The company's commercial products include Zejula for the treatment of breast cancer and non-small cell lung cancer; Optune, a device that delivers tumor treating fields; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other lymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; TPX-0022, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin-17; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. It has development, license, and collaboration agreements with GlaxoSmithKline; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; Incyte Corporation; Regeneron Ireland Designated Activity Company; Turning Point Therapeutics Inc; Cullinan Pearl Corp.; Takeda Pharmaceutical Company Limited; Schrödinger, Inc.; argenx BV; and Geneseeq Technology Inc. The company was incorporated in 2013 and is headquartered in Shanghai, China. Address: Jinchuang Plaza, Shanghai, China, 201210
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service